{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497785,"version":"4.8.0"},"reference-count":82,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Desmopressin increases plasma factor VIII and von Willebrand factor in non-severe hemophilia A (Hem A) and type 1 von Willebrand disease (VWD), following intravenous infusions, subcutaneous injections, or nasal spray. This medication, with almost 50 years of clinical experience and proven safety and efficacy, is often unavailable. Thus, there is a need to establish how many patients can benefit from it and how many bleeding episodes can be treated. We reviewed the literature to estimate the global prevalence of symptomatic patients with VWD type 1 and non-severe Hem A, the incidence of bleeds, and the rate of responsiveness to desmopressin. Real-world data indicate that 1.7 patients with VWD per 100,000 seek care in specialized centers. Of them, 1.15 per 100,000 have type 1 VWD and 80% are reported to respond to desmopressin. In type 1 VWD, the estimated frequency of bleeds treatable with desmopressin are 2.5 events per patient year. Non-severe cases are 45% of all Hem A cases, with a much lower incidence of bleeds than in severe disease (0.4 events \/ patient \/ year). Based on epidemiology, data on the rates of bleeding, and desmopressin responsiveness, we estimated that 84,000 people with VWD type 1 would benefit from desmopressin to treat 210,000 yearly bleeds, and that 81,000 people with non-severe Hem A can be treated yearly for 13,000 bleeds. Desmopressin is an essential therapeutic tool in non-severe Hem A and type 1 VWD that can treat more than 220,000 bleeding episodes successfully, safely, and economically, also in low-income settings with poor access to costly replacement therapies.<\/jats:p>","DOI":"10.3324\/haematol.2025.287572","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:55:54Z","timestamp":1743652554000},"page":"1710-1722","source":"Crossref","is-referenced-by-count":4,"title":["Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A"],"prefix":"10.3324","volume":"110","author":[{"given":"Alessandro","family":"Gringeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gringeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"77133","doi-asserted-by":"crossref","unstructured":"Leebeek FW, Eikenboom JC. Von Willebrand\u2019s disease. N Engl J Med. 2016; 375(21):2067-2080.","DOI":"10.1056\/NEJMra1601561"},{"key":"77134","doi-asserted-by":"crossref","unstructured":"Berntorp E, Fischer K, Hart DP. Haemophilia. Nat Rev Dis Primers. 2021; 7(1):45.","DOI":"10.1038\/s41572-021-00278-x"},{"key":"77135","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands\u2019 diseases. Lancet. 1977; 1(8017):869-872.","DOI":"10.1016\/S0140-6736(77)91197-7"},{"key":"77136","doi-asserted-by":"crossref","unstructured":"Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014; 20(2):158-167.","DOI":"10.1111\/hae.12254"},{"key":"77137","unstructured":"World Federation of Hemophilia Report on the Annual Global Survey. 2023."},{"key":"77138","unstructured":"United Nations Department of Economic and Social Affairs, Population Division. 2024."},{"key":"77139","unstructured":"World Bank Country and Lending Groups. 2024."},{"key":"77140","unstructured":"Von Willebrand disease. 2024."},{"key":"77141","doi-asserted-by":"crossref","unstructured":"Sadler JE, Mannucci PM, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000; 84(2):160-174.","DOI":"10.1055\/s-0037-1613992"},{"key":"77142","doi-asserted-by":"crossref","unstructured":"Stonebraker JS, Iorio A, Lavin M. Reported prevalence of von Willebrand disease worldwide in relation to income classification. Haemophilia. 2023; 29(4):975-986.","DOI":"10.1111\/hae.14810"},{"key":"77143","doi-asserted-by":"crossref","unstructured":"Soucie MJ, Miller CH, Byams VR. Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia. 2021; 27(3):445-453.","DOI":"10.1111\/hae.14263"},{"key":"77144","unstructured":"CDC. Data and Statistics on Von willebrand disease. 2024."},{"key":"77145","unstructured":"AHCDC. von Willebrand disease - 2020 Canada. 2024."},{"key":"77146","unstructured":"ISS-AICE. Registro Nazionale delle Coagulopatie Congenite. 2024."},{"key":"77147","unstructured":"FranceCoag. National statistics: von Willebrand disease. 2021."},{"key":"77148","unstructured":"UKHCDO Annual Report. 2023."},{"key":"77149","unstructured":"\u010cesk\u00fd N\u00e1rodn\u00ed Hemofilick\u00fd Program. 2024."},{"key":"77150","doi-asserted-by":"crossref","unstructured":"Batlle J, Perez-Rodriguez A, Costa Pinto J, Fraga EL, Rodriguez-Trillo Tch A, Fernanda Lopez-Fernandez M. Diagnosis and management of von Willebrand disease in Spain. Semin Thromb Hemost. 2011; 37(5):503-510.","DOI":"10.1055\/s-0031-1281036"},{"key":"77151","doi-asserted-by":"crossref","unstructured":"Lassila R, Holme PA, Landorph A, Petrini P, Onundarson PT, Hillarp A. Nordic Haemophilia Council\u2019s practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Hemost. 2011; 37(5):495-502.","DOI":"10.1055\/s-0031-1281034"},{"key":"77152","doi-asserted-by":"crossref","unstructured":"Akin M, Kavakli K. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience. Semin Thromb Hemost. 2011; 37(5):581-586.","DOI":"10.1055\/s-0031-1281046"},{"key":"77153","doi-asserted-by":"crossref","unstructured":"Ghosh K, Shetty S. Epidemiology, diagnosis, and management of von Willebrand disease in India. Semin Thromb Hemost. 2011; 37(5):595-601.","DOI":"10.1055\/s-0031-1281048"},{"key":"77154","doi-asserted-by":"crossref","unstructured":"Cohan N, Karimi M. Diagnosis and management of von Willebrand disease in Iran. Semin Thromb Hemost. 2011; 37(5):602-606.","DOI":"10.1055\/s-0031-1281049"},{"key":"77155","unstructured":"Qu Y, Nie X, Yang Z. The prevalence of hemophilia in mainland China: a systematic review and meta-analysis. Southeast Asian J Trop Med Public Health. 2014; 45(2):455-466."},{"key":"77156","unstructured":"Ministeiro da Saude. Dados Perfil Coagulopatias Heredit\u00e1rias Brasil \u2013 2023. 2024."},{"key":"77157","doi-asserted-by":"crossref","unstructured":"Rezende SM, Pinheiro K, Caram C, Genovez G, Barca D. Registry of inherited coagulopathies in Brazil: first report. Haemophilia. 2009; 15(1):142-149.","DOI":"10.1111\/j.1365-2516.2008.01907.x"},{"key":"77158","unstructured":"Australian Bleeding Disorders Registry Annual Report 2020-21. 2024."},{"key":"77159","doi-asserted-by":"crossref","unstructured":"Rajagopal R, Smith MP. Diagnosis of von Willebrand disease in South Island, New Zealand. Semin Thromb Hemost. 2011; 37(5):555-559.","DOI":"10.1055\/s-0031-1281042"},{"key":"77160","doi-asserted-by":"crossref","unstructured":"Du P, Bergamasco A, Moride Y, Truong Berthoz F, \u00d6zen G, Tzivelekis S. Von Willebrand disease epidemiology, burden of illness and management: a systematic review. J Blood Med. 2023; 14:189-208.","DOI":"10.2147\/JBM.S389241"},{"key":"77161","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, Tootoonchian E, Ziemele B. von Willebrand disease: gaining a global perspective. Haemophilia. 2023; 29(4):1104-1112.","DOI":"10.1111\/hae.14804"},{"key":"77162","doi-asserted-by":"crossref","unstructured":"de Wee EM, Sanders YV, Mauser-Bunschoten EP. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012; 108(4):683-692.","DOI":"10.1160\/TH12-04-0244"},{"key":"77163","unstructured":"CDC Community Counts. 2024."},{"key":"77164","unstructured":"WFH. WBDR 2023 Data Report. 2024."},{"key":"77165","doi-asserted-by":"crossref","unstructured":"Iorio A, Stonebraker JS, Chambost H. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019; 171(8):540-546.","DOI":"10.7326\/M19-1208"},{"key":"77166","doi-asserted-by":"crossref","unstructured":"Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010; 16(1):20-32.","DOI":"10.1111\/j.1365-2516.2009.02127.x"},{"key":"77167","doi-asserted-by":"crossref","unstructured":"Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia. 2006; 12(1):75-81.","DOI":"10.1111\/j.1365-2516.2006.01189.x"},{"key":"77168","doi-asserted-by":"crossref","unstructured":"den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia. 2009; 15(1):83-90.","DOI":"10.1111\/j.1365-2516.2008.01837.x"},{"key":"77169","doi-asserted-by":"crossref","unstructured":"Seidizadeh O, Eikenboom JCJ, Denis CV. von Willebrand disease. Nat Rev Dis Primers. 2024; 10(1):51.","DOI":"10.1038\/s41572-024-00536-8"},{"key":"77170","doi-asserted-by":"crossref","unstructured":"Federici AB, Barillari G, Zanon E. Efficacy and safety of highly purified, doubly virus-inactivated VWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010; 16(1):101-110.","DOI":"10.1111\/j.1365-2516.2009.02088.x"},{"key":"77171","doi-asserted-by":"crossref","unstructured":"Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011; 105(4):647-654.","DOI":"10.1160\/TH10-11-0697"},{"key":"77172","doi-asserted-by":"crossref","unstructured":"Federici AB, Bucciarelli P, Castaman G. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011; 37(5):511-521.","DOI":"10.1055\/s-0031-1281037"},{"key":"77173","doi-asserted-by":"crossref","unstructured":"Kloosterman FR, Zwagemaker AF, Bagot CN. The bleeding phenotype in people with nonsevere hemophilia. Blood Adv. 2022; 6(14):4256-4265.","DOI":"10.1182\/bloodadvances.2022007620"},{"key":"77174","doi-asserted-by":"crossref","unstructured":"Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia. 1999; 5(5):313-317.","DOI":"10.1046\/j.1365-2516.1999.00342.x"},{"key":"77175","doi-asserted-by":"crossref","unstructured":"Kouides PA, Phatak PD, Burkart P. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000; 6(6):643-648.","DOI":"10.1046\/j.1365-2516.2000.00447.x"},{"key":"77176","doi-asserted-by":"crossref","unstructured":"Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004; 10(2):158-161.","DOI":"10.1046\/j.1351-8216.2003.00832.x"},{"key":"77177","doi-asserted-by":"crossref","unstructured":"Chen YC, Yang L, Cheng SN, Hu SH, Chao TY. von Willebrand disease: a clinical and laboratory study of sixty-five patients. Ann Hematol. 2011; 90(10):1183-1190.","DOI":"10.1007\/s00277-011-1266-4"},{"key":"77178","doi-asserted-by":"crossref","unstructured":"Byams VR, Kouides PA, Kulkarni R. Surveillance of female patients with inherited bleeding disorders in United States haemophilia treatment centres. Haemophilia. 2011; 17(01):Suppl-13.","DOI":"10.1111\/j.1365-2516.2011.02558.x"},{"key":"77179","doi-asserted-by":"crossref","unstructured":"Ragni MV, Machin N, Malec LM. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia. 2016; 22(3):397-402.","DOI":"10.1111\/hae.12898"},{"key":"77180","doi-asserted-by":"crossref","unstructured":"Hassan S, van Balen EC, Smit C. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019. J Thromb Haemost. 2021; 19(10):2394-2406.","DOI":"10.1111\/jth.15424"},{"key":"77181","doi-asserted-by":"crossref","unstructured":"Aznar JA, Luc\u00eda F, Abad-Franch L. Haemophilia in Spain. Haemophilia. 2009; 15(3):665-675.","DOI":"10.1111\/j.1365-2516.2009.02001.x"},{"key":"77182","doi-asserted-by":"crossref","unstructured":"Castaman G, Lethagen S, Federici AB. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008; 111(7):3531-3539.","DOI":"10.1182\/blood-2007-08-109231"},{"key":"77183","doi-asserted-by":"crossref","unstructured":"Stoof SC, Sanders YV, Petrij F. Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thromb Haemost. 2013; 109(3):440-449.","DOI":"10.1160\/TH12-06-0383"},{"key":"77184","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A. WFH guidelines for the management of hemophilia, 3rd ed. Haemophilia. 2020; 26(Suppl 6):1-158.","DOI":"10.1111\/hae.14046"},{"key":"77185","doi-asserted-by":"crossref","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021; 5(1):301-325.","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"77186","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand\u2019s disease and hemophilia A. Blood. 1989; 74(6):1997-2000.","DOI":"10.1182\/blood.V74.6.1997.bloodjournal7461997"},{"key":"77187","doi-asserted-by":"crossref","unstructured":"Heijdra JM, Atiq F, Al Arashi W. Desmopressin testing in von Willebrand disease: lowering the burden. Res Pract Thromb Haemost. 2022; 6(6):e12784.","DOI":"10.1002\/rth2.12784"},{"key":"77188","doi-asserted-by":"crossref","unstructured":"Federici AB, Mazurier C, Berntorp E. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004; 103(6):2032-2038.","DOI":"10.1182\/blood-2003-06-2072"},{"key":"77189","doi-asserted-by":"crossref","unstructured":"Atiq F, Heijdra J, Snijders F. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Adv. 2022; 6(18):5317-5326.","DOI":"10.1182\/bloodadvances.2021006757"},{"key":"77190","doi-asserted-by":"crossref","unstructured":"Leissinger V, Becton D, Cornell C. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001; 7(3):258-266.","DOI":"10.1046\/j.1365-2516.2001.00500.x"},{"key":"77191","doi-asserted-by":"crossref","unstructured":"Castaman G, Lethagen S, Federici AB. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008; 111(7):3531-3539.","DOI":"10.1182\/blood-2007-08-109231"},{"key":"77192","doi-asserted-by":"crossref","unstructured":"Guddati AK, Rosovsky RP, Van Cott EM, Kuter DJ. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. Int J Lab Hematol. 2019; 41(3):325-330.","DOI":"10.1111\/ijlh.12978"},{"key":"77193","doi-asserted-by":"crossref","unstructured":"Chandrakumaran P, Hews-Girard J, Poon MC. Desmopressin (DDAVP) use in patients with von Willebrand disease: a singlecentre retrospective review of test response and clinical outcomes. Haemophilia. 2023; 29(4):1095-1103.","DOI":"10.1111\/hae.14801"},{"key":"77194","doi-asserted-by":"crossref","unstructured":"Nance D, Fletcher SN, Bolgiano DC, Thompson AR, Josephson NC, Konkle BA. Factor VIII mutation and desmopressinresponsiveness in 62 patients with mild haemophilia A. Haemophilia. 2013; 19(5):720-726.","DOI":"10.1111\/hae.12173"},{"key":"77195","doi-asserted-by":"crossref","unstructured":"Di Perna C, Riccardi F, Franchini M. Clinical efficacy and determinants of response to treatment with desmopressin in mild hemophilia A. Semin Thromb Hemost. 2013; 39(7):732-739.","DOI":"10.1055\/s-0033-1354418"},{"key":"77196","doi-asserted-by":"crossref","unstructured":"Loomans JI, Kruip MJHA, Carcao M. Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica. 2018; 103(3):550-557.","DOI":"10.3324\/haematol.2017.180059"},{"key":"77197","doi-asserted-by":"crossref","unstructured":"Hews-Girard J, Rydz N, Lee A, Goodyear MD, Poon MC. Desmopressin in non-severe haemophilia A: test-response and clinical outcomes in a single Canadian centre review. Haemophilia. 2018; 24(5):720-725.","DOI":"10.1111\/hae.13586"},{"key":"77198","doi-asserted-by":"crossref","unstructured":"Zwagemaker AF, Kloosterman FR, Coppens M. Desmopressin for bleeding in non-severe hemophilia A: suboptimal use in a real-world setting. Res Pract Thromb Haemost. 2022; 6(6):e12777.","DOI":"10.1002\/rth2.12777"},{"key":"77199","doi-asserted-by":"crossref","unstructured":"Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild\/moderate haemophilia A. Br J Haematol. 2002; 117(4):947-951.","DOI":"10.1046\/j.1365-2141.2002.03507.x"},{"key":"77200","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemostatic drugs. N Engl J Med. 1998; 339(4):245-253.","DOI":"10.1056\/NEJM199807233390407"},{"key":"77201","doi-asserted-by":"crossref","unstructured":"Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998; 4(4):558-563.","DOI":"10.1046\/j.1365-2516.1998.440558.x"},{"key":"77202","unstructured":"th WHO Model List of Essential Medicines (April 2015). 2024."},{"key":"77203","doi-asserted-by":"crossref","unstructured":"Brignardello-Petersen R, El Alayli A, Husainat N. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Adv. 2022; 6(1):121-128.","DOI":"10.1182\/bloodadvances.2021005666"},{"key":"77204","doi-asserted-by":"crossref","unstructured":"Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012; 18(1):25-33.","DOI":"10.1111\/j.1365-2516.2011.02573.x"},{"key":"77205","doi-asserted-by":"crossref","unstructured":"Franchini M, Targher G, Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol. 2007; 86(10):699-704.","DOI":"10.1007\/s00277-007-0343-1"},{"key":"77206","doi-asserted-by":"crossref","unstructured":"Batty P, Austin SK, Khair K. Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. Br J Haematol. 2017; 176(5):796-804.","DOI":"10.1111\/bjh.14543"},{"key":"77207","unstructured":"Desmopressin acetate nasal spray shortage. 2025."},{"key":"77208","unstructured":"FDA Drug Shortages. Current and resolved drug shortages and discontinuations reported to FDA. 2025."},{"key":"77209","doi-asserted-by":"crossref","unstructured":"Berger K, O\u2019Rourke RH, Di Minno MND. Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals. Haematologica. 2025; 110(3):673-682.","DOI":"10.3324\/haematol.2024.285647"},{"key":"77210","unstructured":"Hemophilia Federation of America. Important update regarding availability of Stimate. 2024."},{"key":"77211","unstructured":"Gringeri A, De Giorgi G, Hval JH. A new desmopressin nasal spray provides a safe and effective treatment solution for people with VWD type 1 and non-severe haemophilia. Haemophilia. 2025; 31(S1):PO244."},{"key":"77212","unstructured":"Orphanet. Von Willebrand disease. 2024."},{"key":"77213","unstructured":"Johnsen J. Von Willebrand disease. 2009."},{"key":"77214","doi-asserted-by":"crossref","unstructured":"Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010; 8(1):213-216.","DOI":"10.1111\/j.1538-7836.2009.03661.x"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12014\/78268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12014\/78610","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12014\/78268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:29Z","timestamp":1794046109000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":82,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.287572","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}